Used in targeted drug delivery systems, this antibody enables the extension of therapeutic half-life by binding to human serum albumin (HSA) in circulation. This interaction leverages albumin’s long half-life to improve pharmacokinetics of fused or conjugated drugs, such as biologics or peptides. It is particularly useful in developing albumin-binding therapeutics for diabetes, oncology, and chronic inflammatory diseases. The technology enhances drug stability and reduces dosing frequency. It also supports the development of multispecific antibodies where improved serum retention is critical. Applications include fusion proteins, half-life extension platforms, and novel biologics engineering.